Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression

Babinkostova, Zoja; Stefanovski, Branislav

doi:10.1007/s13167-011-0103-0

Cited by 6 publications

(4 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This partially contradicts previously published data suggesting that depressive and negative symptoms considerably overlap and that it is hence difficult to differentiate between both ( 21 ). The association between negative symptoms and depressive symptoms has not been sufficiently investigated and results are inconsistent ( 22 ).…”

Section: Discussioncontrasting

confidence: 99%

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis

et al. 2022

View full text Add to dashboard Cite

IntroductionSchizophrenia is a severe psychiatric disorder with a large symptomatic heterogeneity. Moreover, many patients with schizophrenia present with comorbid psychiatric symptoms or disorders. The relation between depressive symptoms and negative symptoms, such as blunted affect, alogia, anhedonia, asociality and avolition, is particularly intriguing. The negative symptoms can be primary or secondary of depression or overlapping with depressive symptoms. The aim of the present network analysis was to better understand the interactions between depressive symptoms and the different symptoms of schizophrenia and to investigate whether negative symptoms and depressive symptoms can be better delineated.MethodsA network analysis on the baseline item scores of the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) from the cariprazine-risperidone study in patients with predominant negative symptoms (PNS) was performed. The connections between all these symptoms (PANSS and CDSS) were investiged: node strength and network centrality were estimated and the Mohr 5-factor model of the PANSS was applied to test the validity of its different symptoms clusters.ResultsAcross 460 patients with schizophrenia and PNS, the most central symptom (largest node strength) was depression (PANSS) followed by depression (CDSS), anxiety, lack of judgment and insight and tension. The PANSS negative symptom cluster together and was only poorly connected with CDSS depresson symptoms. The Mohr 5 factor model was clearly recognized in the overall clustering of symptoms.ConclusionThis network analysis suggests that depression and anxiety symptoms are the most central in this PNS patient population, despite the baseline low depression scores, and that negative symptoms are a clearly independent symptom cluster that can be delineated from depressive symptoms.

show abstract

Section: Discussioncontrasting

confidence: 99%

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…According to Naber et al (2013) , fewer symptoms of depression and higher quality of life in schizophrenic patients can predict early recovery in psychopathology, quality of life, and well-being. The studies conducted by Babinkostova et al (2011) , Kao et al (2011) , Renwick et al (2012) , and Conton et al (2010), Priebe et al (2011) also confirm this result. In a study titled “A comparative study on quality of life of patients of schizophrenia with and without depression”, Dan et al, (2011) showed that the overall score of depression had no relationship with the quality of life in schizophrenic patients; however, symptoms of psychopathology had a strong negative correlation with the quality of life.…”

Section: Discussionsupporting

confidence: 53%

“…Moreover, drug therapy in schizophrenic patients must be accompanied by psychosocial interventions. Early diagnosis and timely interventions improve the quality of life and reduce the severity of the illness in such patients ( Babinkostova et al, 2011 ). The close relationship between major depression and schizophrenia supports the hypothesis that these two disorders may be from the same pathology or be a result of it ( Hafner, 2005 ; Muller et al, 2006 ).…”

Section: Introductionmentioning

confidence: 99%

Study of Relationship Between Depression and Quality of Life in Patients With Chronic Schizophrenia

Shargh¹,

Rostami²,

Kosari³

et al. 2015

GJHS

View full text Add to dashboard Cite

Depression is among the personality traits of schizophrenic patients, which results from psychotic features or is a consequence of a period of psychosis. Depression in schizophrenic patients is one of the important factors affecting their quality of life. The study population of this descriptive and analytic study consists of patients with chronic schizophrenia in Zahedan in 2014. The sample included 60 patients who simultaneously suffered from depression and were selected using random sampling (30 males and 30 females). The research instruments included the Schizophrenia Quality of Life Scale (SQLS) and the Beck Depression Inventory (the inventory was filled out by the tester). In order to form a statistics analysis, we used Pearson correlation and regression multivariate. Investigating the study hypotheses showed that there was a negative correlation between the high level of depression and low quality of life. the relationship between depression and the quality of life subscales showed that in women, the variable of symptoms and complications was a significant predictor; however, the other two variables (energy and motivation and psychosocial) were not significant predictors. In case of men, psychosocial variable was a significant predictor; however, the other two variables (energy and motivation and symptoms and complications) were not significant predictors. In general, depression on these patients makes discontent of life on them; therefore, elimination of their depression on their treatment is necessary.

show abstract

“…While there is a plethora of literature to support the efficacy of the novel antipsychotics olanzapine, risperidone, and quetiapine in improving depressive symptoms in patients with schizophrenia, these results have been viewed as very preliminary by some investigators 29. However, analysis of variance did not show significant differences in weight changes between the three treatment groups (Table 3).…”

Section: Discussionmentioning

confidence: 96%

Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study

Gabriel¹

2013

NDT

View full text Add to dashboard Cite

ObjectivesThe purpose of this study was to compare the effectiveness of novel antipsychotics in the treatment of psychotic depression.MethodConsecutive patients who were admitted (n = 51) with a confirmed diagnosis of major depression with psychotic features (delusions or hallucinations or both) participated in this open-label, naturalistic study. All patients were treated with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) (citalopram or venlafaxine extended release [XR]), and atypical antipsychotic agents were added, as tolerated, during the first week of initiating the citalopram or venlafaxine. There were patients (n = 16) who received risperidone, who received quetiapine (n = 20), and who received olanzapine (n = 15), as an adjunctive treatment to either citalopram or venlafaxine for at least 8 weeks. Outcome measures included the Clinical Global Impression-Severity subscale (CGI-S), as the primary outcome measure, as well as the Hamilton Rating Scale for Depression-21 item (HAM-D21) and the Brief Psychiatric Rating Scale (BPRS). Tolerance to treatments and weight changes were monitored over the period of the trial.ResultsAll patients completed the trial with no drop outs. At 8 weeks, there was a statistically significant (P < 0.001) clinical improvement in all outcome measures for both the depressive and psychotic symptoms, for all three groups of atypical adjunctive treatments. Utilizing analysis of variance (ANOVA), there were no significant differences between the three adjunctive treatment groups in outcome measures. The three antipsychotic agents were equally tolerated. At 8 weeks there was slight increase in weight in the three treatment groups, which was statistically significant (P > .01) in the olanzapine group.ConclusionQuetiapine, risperidone, and olanzapine, given as adjunctive treatment with SSRIS or SNRIs can significantly and equally improve depressive and psychotic symptoms, in the short-term treatment of major depression with psychotic features. The author recommends that large controlled trials be conducted to examine the differences in long-term efficacy and tolerance between the atypical antipsychotic agents, in the treatment of major depression with or without psychotic features.

show abstract

Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression

Cited by 6 publications

References 77 publications

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis

Study of Relationship Between Depression and Quality of Life in Patients With Chronic Schizophrenia

Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study

Contact Info

Product

Resources

About